Following the read-out of Guardant Health’s ECLIPSE study, we hosted a KOL discussion on how the results and potential introduction of liquid biopsy might influence the market for CRC screening. We were joined by one primary care physician (Dr. Gary Cohen, North Shore Physicians Group) and one gastroenterologist (Dr. Jatin Roper, Duke U. School of Medicine) to get two differing opinions on the ECLIPSE results and potential value of a blood test in the screening paradigm. Topics of discussion also included adoption of non-invasive diagnostics for colorectal cancer screening, such as Cologuard and FIT, as well as recent trends around patient care and screening practices.